SCHEMBL20612876

SCHEMBL20612876

CN1Cc2c(O)cccc2NC1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 6/20 0.54
CREBBP Q92793 2/20 0.54
CRBN Q96SW2 2/20 0.39
HPGD P15428 1/20 0.39
GFER P55789 1/20 0.39
ACE P12821 1/20 0.38
MMP13 P45452 1/20 0.38
KMT2A Q03164 1/20 0.37
PARP1 P09874 1/20 0.37
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
DRD2 P14416 1/20 0.35
DRD1 P21728 1/20 0.35
DRD5 P21918 1/20 0.35
DRD3 P35462 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
CDK5 Q00535 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4613887 0.81 BRD4 (0.56) BRD4CREBBPCRBNACEMMP13
SCHEMBL19657830 0.81 BRD4 (0.56) BRD4CREBBPCRBNACEMMP13
SCHEMBL3598100 0.81 BRD4 (0.56) BRD4CREBBPCRBNACEMMP13
SCHEMBL29704455 0.81 BRD4 (0.56) BRD4CREBBPCRBNACEMMP13
SCHEMBL3598102 0.79 BRD4 (0.54) BRD4CREBBPCRBNACEMMP13
SCHEMBL13383385 0.78 BRD4 (0.53) BRD4CREBBPCRBNACEMMP13
SCHEMBL30116170 0.77 CDK5 (0.52) BRD4CREBBPKMT2ADRD2DRD1
SCHEMBL20597216 0.77 CDK5 (0.52) BRD4CREBBPKMT2ADRD2DRD1
SCHEMBL19370098 0.71 CRBN (0.48) CRBNHPGDKMT2APARP1LMNA
SCHEMBL677636 0.71 BRD4 (1.00) BRD4CREBBPCRBNMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851079-B2 Piperidine derivative OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-12-01 US disclosed
US-20190040039-A1 PIPERIDINE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-02-07 US disclosed
EP-3421454-A1 PIPERIDINE DERIVATIVE Otsuka Pharmaceutical Co., Ltd. (JP) 2019-01-02 EP disclosed
CN-1720238-B Neurologically-active compounds PRANA BIOTECHNOLOGY LTD 2011-08-03 CN disclosed
CN-1720238-A Neurologically-active compounds PRANA BIOTECHNOLOGY LTD (AU) 2006-01-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10851079-B2 Piperidine derivative EP300, SLC11A2, TBC1D5 BRD4 150/4885CREBBP 191/4885CRBN 4779/4885
US-20190040039-A1 PIPERIDINE DERIVATIVE EP300, SLC11A2, TBC1D5 BRD4 150/4885CREBBP 191/4885CRBN 4779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.